Treatment of BPH with Demonstrable Prostatic Enlargement (Volume >30 g, PSA >1.5 ng/mL, or Palpable DRE)

This protocol applies to men with benign prostatic hyperplasia in whom prostatic enlargement has been objectively confirmed — a distinction that directly determines which treatments are indicated.

Clinical Scenario

Prostatic enlargement is established by one or more of the following criteria:

Prostate volume >30 g on imaging
Prostate-specific antigen (PSA) >1.5 ng/mL
Palpable prostate enlargement on digital rectal exam (DRE)

Treatment Approach

In patients meeting these criteria, the evidence supports use of 5-alpha reductase inhibitor therapy — as monotherapy or as part of a combination regimen — with further options depending on the full clinical picture.

Complete regimen details, agent selection, and sequencing are available in the full structured protocol below.

Treatment Goals

IPSS decrease of more than 3 points from baseline
Prostate volume reduction of 15–25% at 6 months

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/JU.0000000000003698

5-ARI monotherapy should be used as a treatment option in patients with LUTS/BPH with prostatic enlargement as judged by a prostate volume of >30g on imaging, a prostate specific antigen (PSA) >1.5ng/mL, or palpable prostate enlargement on digital rectal exam (DRE).
5-ARI in combination with an alpha blocker should be offered as a treatment option only to patients with LUTS associated with demonstrable prostatic enlargement as judged by a prostate volume of >30g on imaging, a PSA >1.5ng/mL, or palpable prostate enlargement on DRE.
5-ARIs alone or in combination with alpha blockers are recommended as a treatment option to prevent progression of LUTS/BPH and/or reduce the risks of urinary retention and need for future prostate-related surgery.
For IPSS this is a difference of >3 points.
This, in turn, leads to a reduction in the overall androgenic growth stimulus in the prostate, an increase in apoptosis and atrophy, and ultimately a shrinkage of the organ ranging from 15–25% measured at six months.

View source ↗